Biotechnology Industry · global
Alcon Acquires Neurotech for $550 Million, Adding Retinal Cell Therapy Encelto
By enabling living cells to continuously release a protective protein inside the eye, Encelto brings the first approved therapy to a rare retinal disease. With Alcon taking over, the next step is to translate that approval into treatment accessible to more patients.
For patients with macular telangiectasia type 2 (MacTel type 2), central vision may gradually diminish as the retina degenerates. Encelto, the first therapy approved in the United States for this disease, now has a new commercial backer: Alcon announced on October 20 that it had acquired Neurotech Pharmaceuticals, the therapy’s developer, adding an implantable intraocular cell therapy to its retinal portfolio.
Alcon has paid $550 million for the acquisition, with potential additional payments subject to commercial milestones and other conditions. The announcement did not disclose a cap on those additional payments. Both the *Orange County Business Journal* and ophthalmology publication *Retinal Physician* reported the transaction; the latter also confirmed that Encelto remained available only in the United States at the time of the acquisition.
Encelto was approved by the U.S. Food and Drug Administration (FDA) in March 2025 for adults with idiopathic macular telangiectasia type 2. This is a bilateral neurodegenerative disease involving localized retinal cell loss and vascular changes that may cause irreversible damage to central vision. The development reported here concerns a change in the therapy’s ownership and an expanded commercial strategy, rather than an additional indication.
The therapy encapsulates genetically engineered allogeneic retinal pigment epithelial cells in a semipermeable capsule, which is then surgically implanted into the eye’s vitreous cavity. The cells continuously produce and release recombinant human ciliary neurotrophic factor (rhCNTF), allowing the protein to reach the retina and help protect light-sensing cells. The treatment approach is intended to slow cellular degeneration rather than replace photoreceptor cells that have already been lost.
FDA review materials indicate that two pivotal trials showed Encelto slowed the loss of retinal ellipsoid zone area compared with sham surgery controls; this imaging measure reflects the extent of photoreceptor damage. These results support its retinal protective effect but should not be interpreted as showing that it can restore vision that has already been damaged.
The benefits of the cell therapy must also be weighed against the risks of implantation surgery. Risks listed in the prescribing information include intraocular infection, retinal tears or detachment, vitreous hemorrhage, cataracts, and delayed adaptation to darkness. Severe vision loss has also occurred. Treatment therefore requires an ophthalmologist experienced in vitreoretinal surgery, and patient access also depends on the availability of corresponding medical services.
Neurotech CEO Richard Small said Alcon’s global scale and commercial capabilities could help expand patient access to Encelto. For Alcon, the transaction extends its existing retinal surgery business into cell therapy; for patients, the practical impact will depend on whether supply and treatment services can expand. The acquisition announcement did not provide a launch timeline outside the United States, and the addition of global distribution channels does not mean approval has been obtained in other regions.